Eli Lilly will raise UK private prices for Mounjaro by up to 170 percent from September 2025, with the highest dose set to ...

As results season winds down, Dan Jones and team discuss a property group’s results, alternative ways to find bargain stocks and Novo Nordisk vs Eli Lilly ...

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

Down here, I begin to think that we are too negative on it, but I am very upset with Lilly in the way they handled this, and ...

The injection was initially licensed to treat type 2 diabetes, but is now also prescribed to help with weight loss ...

Eli Lilly is to raise the UK list price of its weight-loss and type 2 diabetes treatment Mounjaro by up to 170pc to be in line with other European markets, it has said, as the pharma industry responds ...

At least 500,000 people in the UK take either Mounjaro or Wegovy, another weight-loss jab, through private prescriptions ...

Modi reinforced his previous recommendations to address the crisis, urging families to purchase 10% less cooking oil, and ...

Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...

Superluminal partners with Eli Lilly to advance AI-driven small molecule therapeutics for cardiometabolic diseases.

The pharmaceutical company said the move is intended to "address pricing inconsistencies compared with other developed ...

Superluminal Medicines Inc. and Eli Lilly and Co. are collaborating in a deal to develop cardiometabolic disease and obesity therapies by aiming at undisclosed G protein-coupled receptor targets. The ...